Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,900,000 shares, a decline of 17.7% from the August 15th total of 2,310,000 shares. Based on an average daily volume of 374,600 shares, the days-to-cover ratio is presently 5.1 days. Currently, 3.9% of the company’s shares are short sold.

Insider Activity

In other Enfusion news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the sale, the insider now directly owns 198,913 shares in the company, valued at $1,613,184.43. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 36.44% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enfusion

A number of large investors have recently modified their holdings of the company. Swiss National Bank raised its holdings in shares of Enfusion by 17.4% in the 4th quarter. Swiss National Bank now owns 58,100 shares of the company’s stock worth $564,000 after acquiring an additional 8,600 shares during the last quarter. Azora Capital LP purchased a new stake in shares of Enfusion in the fourth quarter worth approximately $134,000. Scalar Gauge Management LLC bought a new position in shares of Enfusion in the fourth quarter valued at approximately $1,993,000. Brown Capital Management LLC boosted its position in shares of Enfusion by 6.5% during the fourth quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after buying an additional 724,502 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Enfusion by 5.7% during the fourth quarter. Wellington Management Group LLP now owns 489,364 shares of the company’s stock worth $4,747,000 after buying an additional 26,464 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Trading Up 3.9 %

ENFN opened at $8.73 on Wednesday. The company has a fifty day moving average price of $8.52 and a two-hundred day moving average price of $8.87. Enfusion has a 1-year low of $7.52 and a 1-year high of $10.45. The company has a market cap of $1.12 billion, a P/E ratio of 291.00, a price-to-earnings-growth ratio of 2.23 and a beta of 0.90.

Enfusion (NYSE:ENFN) last issued its earnings results on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $49.46 million during the quarter, compared to the consensus estimate of $50.27 million. Enfusion had a net margin of 1.98% and a return on equity of 6.17%. On average, research analysts forecast that Enfusion will post 0.07 EPS for the current fiscal year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.